Back to search

National and Kapodistrian University of Athens

Κατασκευή, απομόνωση και παραγωγή ανασυνδυασμένων τμημάτων ανθρώπινων αντισωμάτων έναντι καρκινικών αντιγόνων

Abstract

dc:description

A critical point during the infiltration and migration of cancer cells is the degradation of the extracellular space. Major components of this process are metalloproteinases (MMPs), which are regulated by several factors, including EMMPRIN, which is a major regulator of the expression of MMPs. EMMPRIN is a transmembrane protein detected in abundance at the membrane of many types of cancer cells. It belongs to the immunoglobulin superfamily and is also known as basigin or CD147 or EMMPRIN. It consists of a 185 amino acid extracellular region containing two immunoglobulin-like domains (IgI and IgII), a 24 amino acid transmembrane region and a cytoplasmic domain of 39 amino acids. The extracellular domain contains three conserved N-glycosylation sites (one in IgI and two in IgII), which are very diverse in their glycosylation. There are molecules with high levels ofglycosylation (HG-CD147), while others are less glycosylated (LG-CD147). The increased glycosylation of EMMPRIN in cancer suggests that glycosylation contributes to the induction of MMPs.The important role of EMMPRIN during the migration of cancer cells makes this molecule a potential therapeutic target and the isolation of molecules that could inhibit its action, a promising strategy. The purpose of this study was to isolate human antibodies against EMMPRIN and use them as therapeutic molecules in order to inhibit the activity of EMMPRIN and consequently the metastasis of cancer. For this purpose, a library of human antibodies of a patient with breast cancer HER2+ was used, which was constructed with the technology of "phage-antibody". The library was constructed with the use of infiltrated lymph node B cells, with the cDNA coding the Fab portion of antibody (VH-CH1 and VL-CL) being amplified by PCR and then cloned in the phagemid expression vector pComb3H.The selection of specific phage-antibody required the antigen in large amounts and high purity. The production of the antigen, which in this case was the extracellular domain of EMMPRIN (ECD-EMMPRIN, ExtraCellular Domain), was performed to the yeast Pichia pastoris, a system that offers high expression of soluble recombinant protein, proper refolding and post-translational modifications. The recombinant protein was isolated from the culture medium by affinity chromatography (Ni2+-NTA) and then tested with gelatin zymography assay for its ability to induce MMP-2. After incubating skin fibroblasts with the recombinant protein, there was a dose dependent increase in activity of the active form of MMP-2 (65 kDa). The results showed 3.53, 9.57, 5.15 and 17.36 fold increase in induction of MMP-2 by adding 1.6, 3.2, 6.4, and 12.8 μg/well ECD-EMMPRIN, respectively, compared with fibroblasts that had not received exogenous recombinant protein (negative control). The increase of MMP-2 was statistically significant with the addition of 6.4 μg/well ECD-EMMPRIN, while the effect was not significant when 12.8 μg/well was added (p = 0.999).Then, ECD-EMMPRIN was used as substrate for the isolation of a human antibody, which was expressed on the surface of filamentous bacteriophage as a Fab portion through repeated cycles of selection (biopanning). Among all the clones isolated from the library and analysed by DNA «fingerprinting» and sequencing, only one (Fab7) with the higher specificity against ECD-EMMPRIN was ultimately strengthened and further amplified. Also, the whole antibody (mAb7) was constructed after subcloning of the cDNA regions coding for the heavy and light chains of Fab7 to pIgG1 vector for expression in the culture supernatant of mammalian cells CHO. Fab7 and mAb7 were isolated and cultured on a large scale for further analysis. Immunoprecipitation experiments showed that Fab7 and mAb7 were specific for natural EMMPRIN, while Western analysis showed that they recognized molecules with high glycosylation (HG-EMMPRIN). Subsequently, the ability of Fab7 and mAb7 to inhibit metastatic cells of breast and ovarian cancer cell lines was investigated by "wound healing" and "matrigel invasion assays". The antibody isolated against ECD-EMMPRIN, either as Fab portion or as whole monoclonal antibody, was not able to inhibit the metastatic potential of breast and ovarian cancer cells. In contrast, both Fab7 and mAb7 were able to induce high levels of MMPs compared to control sample in zymography experiments.The above results indicate that the antibody isolated against ECD-EMMPRIN does not inhibit the activity of EMMPRIN related to the induction of MMP-2, but instead it seems to reinforce it. For this reason, it was considered necessary to use smaller parts, such as the IgI and IgII extracellular subdomains of EMMPRIN, for the selection of recombinant human function blocking antibodies. The use of smaller area for the selection of antibodies cycles of biopanning, may assist to a more targeted selection. The choice of IgII as antigen selection – besides IgI domain which is considered bibliographically as the responsible domain for the induction of MMPs –was due to some evidence that imply this kind of action. At the same time, it was considered necessary to elucidate the contribution of subregions IgI and IgII to the induction of MMPs and the role of glycosylation in this process. For this reason,except for the subcloning and expression of glycosylated IgI and IgII portions of ECD-EMMPRIN in yeast P.pastoris, these domains were subcloned and expressed in the bacterium E.coli in order to produce their non-glycosylated counterparts. In the present study, the ability of ECD-EMMPRIN subregions IgI and IgII to induce MMPs was initially tested. Then, they were used as substrates for the scanning of the human antibody library in order to isolate an antibody that could inhibit the activity of EMMPRIN.Zymography experiments on fibroblasts incubated with the glycosylated IgI and IgII showed that they could significantly induce the expression of metalloproteinase-2 (MMP-2). This induction was higher at 37.54, 15.07 and 6.27 times respectively, compared to fibroblasts which had not undergone any exogenous effect (negative control). The proteins produced in bacteria and had no post-translational modifications could not induce significantly the production of MMP-2.The statistical analyses performed between glycosylated and non-glucosylated forms, showed that only the glycosylated forms of ECD-EMMPRIN and IgII-EMMPRIN proteins could satisfactory induce MMP-2. The IgI-EMMPRIN had no statistically significant difference in expression levels of MMP-2 between the glycosylated and the non glycosylated form. The inducive capacity of ECD-EMMPRIN, IgI and IgII-EMMPRIN was also investigated by Western Blot analysis. The protein analysis of cell extracts revealed that the expression of MMP-2 was induced only in cells which were incubated with the glycosylated molecules ECD-EMMPRIN, IgI-EMMPRIN and IgII-EMMPRIN, while cells incubated with recombinant molecules produced in bacteria did not have any statistically significant expression of MMP-2. In addition, experiments with concentrated cell supernatants, showed that only the glycosylated forms of ECD-EMMPRIN, IgII-EMMPRIN and much less of IgI-EMMPRIN was sufficient to stimulate the secretion of MMP-2 in the supernatant of the fibroblasts.To further elucidate the mechanism involved in the induction of MMP-2 from the glycosylated proteins ECD-EMMPRIN, IgI-EMMPRIN and IgII-EMMPRIN, Quantitative Polymerase Chain Reaction (Q-PCR) in primary fibroblast cultures was performed. The results showed that there was no statistically significant difference in the mRNA levels of MMP-2 between samples incubated with the glycosylated and unglycosylated extracellular domains of EMMPRIN. This result suggests that the activation of the expression of MMP-2 from the glycosylated forms of the recombinant proteins is not due to transcriptional changes but possibly by post-transcriptional / translational modifications. In conclusion, this study showed that:1) The glycosylation of the extracellular domains of EMMPRIN induce expression of MMP-22) The IgII subdomain of ECD-EMMPRIN is involved in this processThe glycosylated forms of IgI-EMMPRIN and IgII-EMMPRIN were used as substrates for the screening of the human "phage-antibody" library, which was isolated in our lab and was mentioned earlier, in order to isolate inhibitory anti-EMMPRIN antibodies. For this reason, the selection process was repeated but in both cases (whether IgI or IgII was used as a substrate) but did not lead to the isolation of a specific antibody. The inability to find an antibody able to inhibit the activity of EMMPRIN may be due to several factors: a) it is likely that the combination of heavy and light chains during construction of the library does not reflect the in vivo situation of the infiltrated B lymphocytes of the patient, although diversity of the library was satisfactory. b) the phage-antibody library was created by the B lymphocytes infiltrated to the lymph node of a patient with breast cancer who was positive for HER-2/neu. It is likely that the patient does not have antibodies with inhibitory activity against EMMPRIN and thus neither does the library of phage-antibody constructed by these cells. c) It is possible that the antibody isolated from the library interacts with EMMPRIN and forms heterodimers, which then activate the expression of MMPs, as it is known that EMMPRIN belongs to the immunoglobulin superfamily and structurally resembles to the antibody. However, this is difficult to elucidate as there is no longer any biological material left from this patient.These results are deterrent for the use of the antibody in cases where tumors overexpress EMMPRIN but it could contribute actively in situations where there is a vital need for production of MMPs such as wound healing, tissue remodeling and angiogenesis

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papadimitropoulou, Adriana
  • Παπαδημητροπούλου, Ανδριάνα

Subjects

dc:subject × 11

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/50037

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papadimitropoulou, Adriana; Παπαδημητροπούλου, Ανδριάνα. Κατασκευή, απομόνωση και παραγωγή ανασυνδυασμένων τμημάτων ανθρώπινων αντισωμάτων έναντι καρκινικών αντιγόνων. National and Kapodistrian University of Athens, 2014. http://hdl.handle.net/10442/hedi/50037